“We think it is worth noting that 98% of the annual January list price increases were taken by this time last year,” Raymond James analyst Elliot Wilbur wrote. “Clearly, more caution is in the air and many major multinationals such as Pfizer and Novartis, which found themselves making the headlines several months back, have yet to implement their January increases.”

Source: Los Angeles Times January 02, 2019 22:30 UTC